 |
市場調查報告書
商品編碼
1457981
全球來那度胺市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測Global Lenalidomide Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
全球來那度胺市場需求預計將從2023年的182.3億美元達到近313億美元的市場規模，2024-2032年研究期間CAGR為6.19%。
來那度胺是一種用於治療某些癌症的藥物，特別是多發性骨髓瘤和骨髓增生異常綜合症。它屬於一類被稱為免疫調節劑的藥物，致力於改變免疫系統的反應並抑制癌細胞的生長。來那度胺通常與其他療法合併使用以提高療效。
市場動態
在血液系統惡性腫瘤，特別是多發性骨髓瘤和骨髓增生異常綜合症盛行率不斷擴大的推動下，來那度胺市場正在顯著成長。來那度胺是一種免疫調節藥物，已證明可以有效治療這些疾病，從而在臨床環境中得到越來越多的採用。此外，正在進行的研究和開發活動探索該藥物治療各種癌症的潛力，有助於其市場擴張。此外，有利的報銷政策和對該藥物治療益處的日益認知促進了市場成長。全球人口老化是與這些血液疾病相關的重要人口因素，進一步推動了對這種藥物的需求。然而，某些因素，例如嚴格的監管要求和潛在的不利副作用，可能會阻礙來那度胺市場。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對來那度胺全球市場的每個細分市場進行了包容性評估。來那度胺產業的成長和趨勢為本研究提供了整體方法。
市場區隔
來那度胺市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。
按類型
- 5毫克膠囊
- 10毫克膠囊
- 15毫克膠囊
- 25毫克膠囊
按申請
- 多發性骨髓瘤 (MM)
- 骨髓增生異常症候群 (MDS)
- 其他應用
按最終用戶
- 醫院
- 癌症治療中心
- 研究機構
區域分析
本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲來那度胺市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
- 全球來那度胺市場佔有率（按地區）（代表圖）
- 全球來那度胺市場佔有率
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。來那度胺市場的主要參與者包括Accord Healthcare、Cipla、Deva Pharma、Dr. Reddy's Laboratories Ltd.、Glenmark Pharmaceuticals、Hetero、Hikma Pharmaceuticals、Lupin Limited、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Torrent Pharmaceuticals Ltd.。 ，Viatris Inc.。本部分包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
目錄
第1章：前言
- 報告說明
- 客觀的
- 目標受眾
- 獨特的銷售主張 (USP) 和產品
- 研究範圍
- 研究方法論
- 市場研究過程
- 市場研究方法論
第 2 章：執行摘要
- 市場亮點
- 全球市場概況
第 3 章：來那度胺 - 產業分析
- 簡介 - 市場動態
- 市場促進因素
- 市場限制
- 機會
- 產業動態
- 波特五力分析
- 市場吸引力分析
- 按類型分類的市場吸引力分析
- 市場吸引力分析：依應用分類
- 最終用戶的市場吸引力分析
- 市場吸引力分析：按地區
第 4 章：價值鏈分析
- 價值鏈分析
- 原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
- 潛在買家名單
- 行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢
第 5 章：全球來那度胺市場分析：按類型
- 按類型概述
- 歷史和預測數據
- 按類型分析
- 5毫克膠囊
- 10毫克膠囊
- 15毫克膠囊
- 25毫克膠囊
第 6 章：全球來那度胺市場分析：依應用分類
- 概述：按應用
- 歷史和預測數據
- 分析：按應用
- 多發性骨髓瘤 (MM)
- 骨髓增生異常症候群 (MDS)
- 其他應用
第 7 章：全球來那度胺市場分析：依最終使用者分類
- 最終用戶概述
- 歷史和預測數據
- 最終用戶分析
- 醫院
- 癌症治療中心
- 研究機構
第 8 章：全球來那度胺市場分析：依地理位置
- 區域展望
- 介紹
- 北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
- 歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
- 亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
- 拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
- 中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析
第 9 章：來那度胺公司的競爭格局
- 來那度胺市場競爭
- 夥伴關係/協作/協議
- 併購
- 新產品發布
- 其他發展
第 10 章：公司簡介
- 公司股份分析
- 市場集中度
- Accord Healthcare
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Cipla
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Deva Pharma
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Dr. Reddy's Laboratories Ltd.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Glenmark Pharmaceuticals
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Hetero
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Hikma Pharmaceuticals
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Lupin Limited
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Sun Pharmaceutical Industries Ltd.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Teva Pharmaceutical Industries Ltd.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Torrent Pharmaceuticals Ltd.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Viatris Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內
The global demand for Lenalidomide Market is presumed to reach the market size of nearly USD 31.3 Billion by 2032 from USD 18.23 Billion in 2023 with a CAGR of 6.19% under the study period 2024 - 2032.
Lenalidomide is a medication used in the treatment of certain cancers, particularly multiple myeloma and myelodysplastic syndromes. It belongs to a class of drugs known as immunomodulatory agents, working to modify the immune system's response and inhibit the growth of cancer cells. lenalidomide is often prescribed in combination with other therapies for improved efficacy.
MARKET DYNAMICS
The lenalidomide market is witnessing significant growth, driven by the expanding prevalence of hematological malignancies, particularly multiple myeloma and myelodysplastic syndromes. Lenalidomide, an immunomodulatory drug, has demonstrated efficacy in treating these conditions, leading to increased adoption in clinical settings. Furthermore, ongoing research and development activities explore the drug's potential for treating various cancers, contributing to its market expansion. Additionally, favorable reimbursement policies and a growing awareness of the drug's therapeutic benefits foster market growth. The rise in aging populations globally, which is a significant demographic factor linked to these hematological disorders, is further fueling the demand for this medication. However, certain factors, such as stringent regulatory requirements and potential adverse side effects, will likely hamper the lenalidomide market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lenalidomide. The growth and trends of lenalidomide industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the lenalidomide market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- 5Mg Capsules
- 10Mg Capsules
- 15Mg Capsules
- 25Mg Capsules
By Application
- Multiple Myeloma (MM)
- Myelodysplastic Syndromes (MDS)
- Other Applications
By End-User
- Hospitals
- Cancer Treatment Centers
- Research Institutes
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Lenalidomide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
- GLOBAL LENALIDOMIDE MARKET SHARE BY REGION (REPRESENTATIVE GRAPH)
- Global Lenalidomide Market Share
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lenalidomide market include Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Hikma Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . LENALIDOMIDE - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY TYPE
- 5.1 Overview by Type
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Type
- 5.4 5mg Capsules Historic and Forecast Sales by Regions
- 5.5 10mg Capsules Historic and Forecast Sales by Regions
- 5.6 15mg Capsules Historic and Forecast Sales by Regions
- 5.7 25mg Capsules Historic and Forecast Sales by Regions
6 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY APPLICATION
- 6.1 Overview by Application
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Application
- 6.4 Multiple Myeloma (MM) Historic and Forecast Sales by Regions
- 6.5 Myelodysplastic Syndromes (MDS) Historic and Forecast Sales by Regions
- 6.6 Other Applications Historic and Forecast Sales by Regions
7 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY END-USER
- 7.1 Overview by End-User
- 7.2 Historical and Forecast Data
- 7.3 Analysis by End-User
- 7.4 Hospitals Historic and Forecast Sales by Regions
- 7.5 Cancer Treatment Centers Historic and Forecast Sales by Regions
- 7.6 Research Institutes Historic and Forecast Sales by Regions
8 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis
9 . COMPETITIVE LANDSCAPE OF THE LENALIDOMIDE COMPANIES
- 9.1. Lenalidomide Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10 . COMPANY PROFILES OF LENALIDOMIDE INDUSTRY
- 10.1. Company Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Accord Healthcare
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
- 10.4. Cipla
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
- 10.5. Deva Pharma
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
- 10.6. Dr. Reddy's Laboratories Ltd.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
- 10.7. Glenmark Pharmaceuticals
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
- 10.8. Hetero
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
- 10.9. Hikma Pharmaceuticals
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
- 10.10. Lupin Limited
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
- 10.11. Sun Pharmaceutical Industries Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
- 10.12. Teva Pharmaceutical Industries Ltd.
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
- 10.13. Torrent Pharmaceuticals Ltd.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
- 10.14. Viatris Inc.
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- Analysis by Type (USD MN)
- 5mg Capsules Market Sales by Geography (USD MN)
- 10mg Capsules Market Sales by Geography (USD MN)
- 15mg Capsules Market Sales by Geography (USD MN)
- 25mg Capsules Market Sales by Geography (USD MN)
- Analysis Market by Application (USD MN)
- Multiple Myeloma (MM) Market Sales by Geography (USD MN)
- Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
- Other Applications Market Sales by Geography (USD MN)
- Analysis by End-User (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Cancer Treatment Centers Market Sales by Geography (USD MN)
- Research Institutes Market Sales by Geography (USD MN)
- Global Lenalidomide Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Lenalidomide Report
- Market Research Process
- Market Research Methodology
- Global Lenalidomide Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Type
- Market Attractiveness Analysis by Application
- Market Attractiveness Analysis by End-User
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Type (USD MN)
- 5mg Capsules Market Sales by Geography (USD MN)
- 10mg Capsules Market Sales by Geography (USD MN)
- 15mg Capsules Market Sales by Geography (USD MN)
- 25mg Capsules Market Sales by Geography (USD MN)
- Global Market Analysis by Application (USD MN)
- Multiple Myeloma (MM) Market Sales by Geography (USD MN)
- Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
- Other Applications Market Sales by Geography (USD MN)
- Global Market Analysis by End-User (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Cancer Treatment Centers Market Sales by Geography (USD MN)
- Research Institutes Market Sales by Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
![來那度胺市場- 依類型（5mg、10mg、15mg、25mg 膠囊）、應用（多發性骨髓瘤[MM]、骨髓增生異常綜合症[MDS]）、最終用戶（醫院、癌症治療中心、研究機構） - 全球預測，2024 年 - 2032](/sample/img/cover/42/default_cover_0.png)
